Skip to content

Released Aug 10, 2023, after the close

10-Q filed Aug 10, 2023, 41 days after period end · 0000950170-23-041416

Q2 2023 · 10-Q
Revenue$10.41M−62.9% vs Q2 2022−17.8% vs Q1 2023
Net Income-$38.52MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.64N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$46,179,000N/M
Operating Cash Flowderived-$31,195,000N/M
Margins · derived
Operating margin-443.5%−374.5 pt vs Q2 2022
Net margin-370.0%−277.4 pt vs Q2 2022

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2021Q2 2020
Revenue$10.41M$28.10M$28.05M$9.47M
Net Income-$38.52M-$26.01M-$6.15M$29.87M
EPS Diluted-$0.64-$0.55-$0.13$0.94

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR